BTAI - BioXcel Therapeutics, Inc.
44.50 +1.50 (3.49%)
After hours: 7:04PM EDT
Chart Events
Relative Strength Index (RSI)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 46.05 |
| Open | 45.97 |
| Bid | 42.89 x 900 |
| Ask | 43.51 x 1200 |
| Day's Range | 42.94 - 47.48 |
| 52 Week Range | 3.76 - 51.83 |
| Volume | 393,640 |
| Avg. Volume | 528,519 |
| Market Cap | 869.086M |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.38 |
| Earnings Date | May 12, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 74.57 |
Fair Value
Related Research
- GlobeNewswire
BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference
NEW HAVEN, Conn., May 28, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- Zacks Small Cap Research
BTAI: Phase 3 Data from SERENITY Trials in July 2020…
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT BioXcel Therapeutics, Inc. (NASDAQ:BTAI) currently has two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer
- GlobeNewswire
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced full enrollment of its pivotal Phase 3 SERENITY trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. The Company expects to report topline data from both trials in July of 2020.
- Motley Fool
BioXcel Therapeutics, Inc. (BTAI) Q1 2020 Earnings Call Transcript
Good morning, everyone, and thank you for joining our conference call to discuss BioXcel Therapeutics' financial results and business highlights for the first-quarter 2020. Joining me for the call today are Richard Steinhart, chief financial officer; Frank Yocca, chief scientific officer; and Vince O'Neill, chief medical officer.
- GlobeNewswire
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020 The Company is assessing data for dose escalation in the.
- GlobeNewswire
BioXcel Therapeutics to Present at the UBS Virtual Global Healthcare Conference
NEW HAVEN, Conn., May 11, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- GlobeNewswire
BioXcel Therapeutics to Present at the BofA Securities Virtual Health Care Conference
NEW HAVEN, Conn., May 07, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.
- GlobeNewswire
BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast
NEW HAVEN, Conn., May 05, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- GlobeNewswire
BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced the initiation of the Phase 2 efficacy portion of the Phase 1b/2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) for treatment emergent Neuroendocrine Prostate Cancer (tNEPC). Initial interim data from this study is expected in the fourth quarter of 2020.
- Simply Wall St.
How BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Can Impact Your Portfolio Volatility
If you're interested in BioXcel Therapeutics, Inc. (NASDAQ:BTAI), then you might want to consider its beta (a measure...
- MarketWatch
Biotech stocks have held up better than the broader market — and these five are potential winners
Landmine No. 1: Smaller biotech companies short on cash will face a funding crunch if the stock market stays down. How to diffuse it: Favor biotech companies that just raised cash, or have enough on hand to cover at least 18 months of cash burn, says Jefferies biotech analyst Michael Yee. Several companies were lucky enough to raise capital right before the biotech group started to fall apart on March 6.
- GlobeNewswire
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that more than one-third of the patients in the Phase 3 SERENITY trials have been enrolled and treated. To date, the company has not observed a change in enrollment rates resulting from the COVID-19 pandemic, and currently maintains previous guidance that SERENITY I & II are expected to be completed by mid-year 2020.
- Zacks Small Cap Research
BTAI: On Track for Multiple Data Readouts in 2020…
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT BioXcel Therapeutics, Inc. (NASDAQ:BTAI) currently has two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer
- GlobeNewswire
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia Strengthened balance.
- ACCESSWIRE
BioXcel Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 9, 2020 / BioXcel Therapeutics, Inc. (BTAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 9, 2020 at 8:30 AM ...
- GlobeNewswire
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2019 Operating and Financial Results Conference Call and Webcast
NEW HAVEN, Conn., March 02, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- Zacks Small Cap Research
BTAI: Financing Strengthens Balance Sheet; Raising Valuation to $92/Share…
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update IND for Opioid Withdrawal Cleared by FDA On February 6, 2020, BioXcel (NASDAQ:BTAI) announced that the FDA has cleared the company’s IND for BXCL501 for the treatment of opioid withdrawal symptoms. The company will soon be initiating the Phase 1b/2 RELEASE trial, which will be a multicenter, randomized, double
- GlobeNewswire
BioXcel Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
NEW HAVEN, Conn., Feb. 26, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- GlobeNewswire
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 2,000,000 shares of common stock at a public offering price of $32.00 per share. In addition, BTI has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock from BTI at the public offering price, less underwriting discounts and commissions. Gross proceeds to BTI from the offering are expected to be approximately $64.0 million, before deducting underwriting discounts and commissions and offering expenses.
- GlobeNewswire
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. In connection with the offering, BTI intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock from BTI. To the extent the underwriters exercise their option to purchase additional shares of common stock, the Company intends to use the net proceeds from the sale of additional shares to repurchase shares of common stock (which shares will then be canceled) from BioXcel Corporation at a price equal to the price paid by the underwriters for such shares in the public offering.
- Benzinga
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...
- GlobeNewswire
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced the initiation of a Phase 2 study by researchers at Yale University designed to measure biomarkers associated with agitation in patients with schizophrenia and the response to treatment with BXCL501. The Company aims to utilize biomarkers to identify additional indications that exhibit the same physiological signals of hyperarousal, expanding the potential use of BXCL501 to new chronic disease indications.
- GlobeNewswire
BioXcel Therapeutics to Present at the 2020 BIO CEO & Investor Conference
NEW HAVEN, Conn., Feb. 07, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.
- Benzinga
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
- GlobeNewswire
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that its Investigational New Drug (“IND”) application for BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”), has received clearance from the U.S. Food and Drug Administration (“FDA”) for the treatment of opioid withdrawal symptoms. “The FDA clearance of our IND application for opioid withdrawal, a fourth indication, is an important step in our plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501,” commented Vimal Mehta, Chief Executive Officer of BTI.
